ClinicalTrials.gg
WithdrawnNCT05504486Updated Jan 30, 2023

Open-label Brexpiprazole fMRI Trial in Adults With Major Depressive Disorder and Anxiety

A Phase 4 interventional study of Brexpiprazole in Major Depressive Disorder (MDD), sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Withdrawn. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-01-30.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 4, Interventional, and Basic science

Why this study was withdrawn
Sponsor strategic decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies testing brexpiprazole in Depressive Disorder, Major — 1 open to participants now, 1 under way, none of them phase 3. brexpiprazole · Depressive Disorder, Major.

Enrollment
23rd of 24
0 · median 189
Started
2022
the only one that year
Phase 4
3 of 24
1 open now
Registered
24th of 24
by date
Lead sponsor
15 of 24
Otsuka Pharmaceutical Development & Commercialization, Inc.

Among the 24 studies testing brexpiprazole in Depressive Disorder, Major, this one is the 23rd largest by enrollment, is the only one that started in 2022, is one of 3 in phase 4, and was the 24th registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

1 of the 24 studies testing brexpiprazole in Depressive Disorder, Major is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About brexpiprazole

brexpiprazole: first FDA approval 2015 (REXULTI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies testing brexpiprazole in Depressive Disorder, Major, or all of them as a file.
02

Study summary

The purpose of this study is to use fMRI to evaluate the effects of brexpiprazole as add-on therapy to antidepressants on brain connectivity in individuals with MDD and symptoms of anxiety, aged 18 to 65.

03

Conditions studied

  • Major Depressive Disorder (MDD)

Keywords

  • Major depressive disorder (MDD)
  • symptoms of anxiety
  • fMRI
  • brain networks
  • modularity
  • community structure
  • brexpiprazole
  • default mode network
  • salience network
  • central executive network
  • functional brain connectivity
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 to 65 year of age
  • Major Depressive Disorder (MDD) with symptoms of anxiety
  • Stable treatment with less than 50% improvement

Exclusion criteria

Exclusion Criteria:

  • to perform fMRI scan
  • Previous exposure to brexpiprazole
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Arm 1

    Brexpiprazole

    Drug: Brexpiprazole

Interventions

  • Oral tablet; take once daily; target daily dose of 2 mg

06

What researchers measure

Primary outcomes

  1. Change in fMRI resting-state salience network community structure from baseline to post-treatment

    Time frame: Week 6

Secondary outcomes

  1. Association between change in resting-state salience network community structure and change in MADRS total score from baseline to post treatment.

    Utilizing Jaccardized Czekanowski index

    Time frame: Week 6

  2. Change in Default Mode Network (DMN) community structure during emotional face viewing from baseline to post-treatment.

    Utilizing Jaccardized Czekanowski index

    Time frame: Week 6

  3. Change in Central Executive Network (CEN) community structure during a working memory task from baseline to post-treatment.

    Utilizing Jaccardized Czekanowski index

    Time frame: Week 6

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Aug 2022; primary completion for Mar 2023, 6 months later.

How these figures are worked out, and which studies are left out of them.

Registered
May 31, 2022
First posted
Aug 17, 2022
StartEst.
Aug 29, 2022
Primary completionEst.
Mar 22, 2023
CompletionEst.
Apr 5, 2023
Last update
Jan 30, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 30, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05504486
Collaborators
H. Lundbeck A/S
Responsible party
Sponsor
First posted
Aug 17, 2022
Start date
Aug 29, 2022 (estimated)
Primary completion
Mar 22, 2023 (estimated)
Completion
Apr 5, 2023 (estimated)
Last update
Jan 30, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brexpiprazole

Start the discussion